CCA
NEOS

Catalyst Capital Advisors’s Neos Therapeutics, Inc NEOS Stock Holding History

Catalyst Capital Advisors’s Portfolio NEOS Stock Details NEOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-205
Closed -$3K – 664
2015
Q4 		$3K Buy
+205
New +$3.09K ﹤0.01% 502

Other funds holding NEOS

SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return

Catalyst Capital Advisors's NEOS Position: Q1 2016 in Review

Catalyst Capital Advisors sold out of Neos Therapeutics, Inc (NEOS) in Q1 2016, closing a stake of 205 shares — an estimated $3K sold.

Catalyst Capital Advisors first reported a position in NEOS in Q4 2015 and held it in 1 quarter. The position peaked at $3K in Q4 2015. 47 funds tracked by Wall St. Rank hold NEOS as of Q1 2016.

  • Catalyst Capital Advisors reported no remaining Neos Therapeutics, Inc position as of Q1 2016 after selling out during the quarter.
  • Catalyst Capital Advisors sold 205 Neos Therapeutics, Inc shares in Q1 2016, an estimated $3K.
  • Catalyst Capital Advisors first reported a position in Neos Therapeutics, Inc in Q4 2015 and held it in 1 quarter.
  • Catalyst Capital Advisors's Neos Therapeutics, Inc position peaked at $3K in Q4 2015.
  • 47 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q1 2016.

Based on Catalyst Capital Advisors's 13F filing for Q1 2016, filed 11 May 2016.